Corindus Vascular Robotics to Report First Quarter 2016 Financial Results on May 5, 2016

2 years ago


Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular roboticstoday announced that it will release financial and business results for the first quarter 2016 after the close of trading on Thursday, May 5, 2016. The Company’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.

Investors interested in listening to the conference call may do so by dialing (877) 201-0168 for domestic callers or (647) 788-4901 for international callers (Conference ID: 94143809), or from the webcast on the “Investor Relations” section of the Company’s website at: Following the call, an audio replay will be available on the Investor Relations section of the Company’s website.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company’s CorPath System is the first FDA-cleared medical device to bring robotic-assisted precision to radial coronary and peripheral procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit “One Stent Program.”

For additional information, visit, and follow @CorindusInc.

Corindus Vascular Robotics, Inc.
Brett Prince, 508-653-3335 ext. 231
Lynn Pieper Lewis, 415-937-5402
Yuliya Kutuzava, 203-504-8230 ext. 131

Stock Information

Investor Toolkit


Follow this blog

Get every new post delivered right to your inbox.

Email address